CITN-07 A Phase II, Open-label, Multicenter, Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand
Clinical Trial Grant
Administered By
Medicine, Medical Oncology
Awarded By
Fred Hutchinson Cancer Research Center
Start Date
September 1, 2014
End Date
December 31, 2018
Administered By
Medicine, Medical Oncology
Awarded By
Fred Hutchinson Cancer Research Center
Start Date
September 1, 2014
End Date
December 31, 2018